These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 28670693)
1. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. Waldschmidt JM; Simon A; Wider D; Müller SJ; Follo M; Ihorst G; Decker S; Lorenz J; Chatterjee M; Azab AK; Duyster J; Wäsch R; Engelhardt M Br J Haematol; 2017 Oct; 179(1):36-49. PubMed ID: 28670693 [TBL] [Abstract][Full Text] [Related]
2. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma. Ren Z; Lantermans H; Kuil A; Kraan W; Arenzana-Seisdedos F; Kersten MJ; Spaargaren M; Pals ST J Hematol Oncol; 2021 Jan; 14(1):11. PubMed ID: 33436043 [TBL] [Abstract][Full Text] [Related]
3. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment. Li W; Ding Q; Ding Y; Lu L; Wang X; Zhang Y; Zhang X; Guo Q; Zhao L Mol Carcinog; 2017 Mar; 56(3):863-876. PubMed ID: 27533597 [TBL] [Abstract][Full Text] [Related]
4. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009 [TBL] [Abstract][Full Text] [Related]
5. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670 [TBL] [Abstract][Full Text] [Related]
6. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079 [TBL] [Abstract][Full Text] [Related]
7. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Hoellenriegel J; Zboralski D; Maasch C; Rosin NY; Wierda WG; Keating MJ; Kruschinski A; Burger JA Blood; 2014 Feb; 123(7):1032-9. PubMed ID: 24277076 [TBL] [Abstract][Full Text] [Related]
8. Blockade of SDF-1/CXCR4 reduces adhesion-mediated chemoresistance of multiple myeloma cells via interacting with interleukin-6. Liu Y; Liang HM; Lv YQ; Tang SM; Cheng P J Cell Physiol; 2019 Nov; 234(11):19702-19714. PubMed ID: 30953364 [TBL] [Abstract][Full Text] [Related]
10. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505 [TBL] [Abstract][Full Text] [Related]
11. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. Ladikou EE; Chevassut T; Pepper CJ; Pepper AG Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579 [TBL] [Abstract][Full Text] [Related]
12. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib. Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750 [TBL] [Abstract][Full Text] [Related]
13. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Nefedova Y; Landowski TH; Dalton WS Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386 [TBL] [Abstract][Full Text] [Related]
14. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254 [TBL] [Abstract][Full Text] [Related]
15. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response. Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622 [TBL] [Abstract][Full Text] [Related]
16. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. Daniel SK; Seo YD; Pillarisetty VG Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281 [TBL] [Abstract][Full Text] [Related]